EP1060269A1 - Production et utilisation d'echantillotheques d'adn normalisees - Google Patents

Production et utilisation d'echantillotheques d'adn normalisees

Info

Publication number
EP1060269A1
EP1060269A1 EP99909874A EP99909874A EP1060269A1 EP 1060269 A1 EP1060269 A1 EP 1060269A1 EP 99909874 A EP99909874 A EP 99909874A EP 99909874 A EP99909874 A EP 99909874A EP 1060269 A1 EP1060269 A1 EP 1060269A1
Authority
EP
European Patent Office
Prior art keywords
genomic dna
dna
library
isolated
population
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99909874A
Other languages
German (de)
English (en)
Other versions
EP1060269A4 (fr
Inventor
Jay Short
Eric J. Mathur
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF Enzymes LLC
Original Assignee
Diversa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/034,724 external-priority patent/US6001574A/en
Application filed by Diversa Corp filed Critical Diversa Corp
Publication of EP1060269A1 publication Critical patent/EP1060269A1/fr
Publication of EP1060269A4 publication Critical patent/EP1060269A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1096—Processes for the isolation, preparation or purification of DNA or RNA cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules

Definitions

  • the present invention relates to the field of production and screening of gene libraries, and more particularly to the generation and screening of normalized genomic DNA libraries from mixed populations of microbes and/or other organisms.
  • the present invention addresses this need by providing methods to isolate the
  • DNA from a variety of sources including isolated organisms, consortias of microorganisms, primary enrichments, and environmental samples, to make libraries which have been "normalized” in their representation of the genome populations in the original samples, and to screen these libraries for enzyme and other bioactivities.
  • the present invention represents a novel, recombinant approach to generate and screen DNA libraries constructed from mixed microbial populations of cultivated or, preferably, uncultivated (or "environmental") samples.
  • libraries with equivalent representation of genomes from microbes that can differ vastly in abundance in natural populations are generated and screened.
  • This "normalization" approach reduces the redundancy of clones from abundant species and increases the representation of clones from rare species.
  • These normalized libraries allow for greater screening efficiency resulting in the isolation of genes encoding novel biological catalysts. .- 4 - Screening of mixed populations of organisms has been made a rational approach because of the availability of techniques described herein, whereas previously attempts at screening of mixed population were not feasible and were avoided because of the cumbersome procedures required.
  • the invention provides a process for forming a normalized genomic DNA library from an environmental sample by (a) isolating a genomic DNA population from the environmental sample; (b) at least one of (i) amplifying the copy number of the DNA population so isolated and (ii) recovering a fraction of the isolated genomic DNA having a desired characteristic; and (c) normalizing the representation of various DNAs within the genomic DNA population so as to form a normalized library of genomic DNA from the environmental sample.
  • the process comprises the step of recovering a fraction of the isolated genomic DNA having a desired characteristic.
  • the process comprises the step of amplifying the copy number of the DNA population so isolated.
  • the step of amplifying the genomic DNA precedes the normalizing step.
  • the step of normalizing the genomic DNA precedes the amplifying step.
  • the process comprises both the steps of (i) amplifying the copy number of the DNA population so isolated and (ii) recovering a fraction of the isolated genomic DNA having a desired characteristic.
  • Another aspect of the invention provides a normalized genomic DNA library formed from an environmental sample by a process comprising the steps of (a) isolating a genomic DNA population from the environmental sample; (b) at least one - 5 - of (i) amplifying the copy number of the DNA population so isolated and (ii) recovering a fraction of the isolated genomic DNA having a desired characteristic; and (c) normalizing the representation of various DNAs within the genomic DNA population so as to form a normalized library of genomic DNA from the environmental sample.
  • the various preferred embodiments described with respect to the above method aspect of the invention are likewise applicable with regard to this aspect of the invention.
  • the invention also provides a process for forming a normalized genomic DNA library from an environmental sample by (a) isolating a genomic DNA population from the environmental sample; (b) at least one of (i) amplifying the copy number of the DNA population so isolated and (ii) recovering a fraction of the isolated genomic DNA having a desired characteristic; and (c) normalizing the representation of various DNAs within the genomic DNA population so as to form a normalized library of genomic DNA from the environmental sample.
  • Another aspect of the invention provides a normalized genomic DNA library formed from an environmental sample by a process comprising the steps of (a) isolating a genomic DNA population from the environmental sample; (b) at least one of (i) amplifying the copy number of the DNA population so isolated and (ii) recovering a fraction of the isolated genomic DNA having a desired characteristic; and (c) normalizing the representation of various DNAs within the genomic DNA population so as to form a normalized library of genomic DNA from the environmental sample.
  • the various preferred embodiments described with respect to the above method aspect of the invention are likewise applicable with regard to this aspect of the invention.
  • Figure 1 is a graph showing the percent of total DNA content represented by G + C in the various genomic DNA isolates tested as described in Example 2. r 6 -
  • DNA can be isolated from samples using various techniques well known in the art (Nucleic Acids in the Environment Methods & Applications, J.T. Trevors, D.D. van Elsas, Springer Laboratory, 1995). Preferably, DNA obtained will be of large size and free of enzyme inhibitors and other contaminants. DNA can be isolated directly from the environmental sample (direct lysis) or cells may be harvested from the sample prior to DNA recovery (cell separation). Direct lysis procedures have several advantages over protocols based on cell separation.
  • the direct lysis technique provides more DNA with a generally higher representation of the microbial community, however, it is sometimes smaller in size and more likely to contain enzyme inhibitors than DNA recovered using the cell separation technique.
  • Very useful direct lysis techniques have recently been described which provide DNA of high molecular weight and high purity (Barns, 1994; Holben, 1994). If inhibitors are present, there are several protocols which utilize cell isolation which can be employed (Holben, 1994). Additionally, a fractionation technique, such as the bis-benzimide separation (cesium chloride isolation) described below, can be used to enhance the purity of the DNA.
  • DNA is preferably fractionated using a density centrifugation technique.
  • a density centrifugation technique is a cesium-chloride gradient.
  • the technique is performed in the presence of a nucleic acid intercalating agent which will bind regions of the DNA and cause a change in the buoyant density of the nucleic acid.
  • the nucleic acid intercalating agent is a dye, such as bis-benzimide which will preferentially bind regions of DNA (AT in the case .- 7 - of bis-benzimide) (Muller, 1975; Manuelidis, 1977).
  • nucleic acid complexed with an intercalating agent such as bis-benzimide
  • an intercalating agent such as bis-benzimide
  • the nucleic acid is fractionated. If the intercalating agent preferentially binds regions of the DNA, such as GC or AT regions, the nucleic acid is separated based on relative base content in the DNA. Nucleic acid from multiple organisms can be separated in this manner.
  • Density gradients are currently employed to fractionate nucleic acids. For example, the use of bis-benzimide density gradients for the separation of microbial nucleic acids for use in soil typing and bioremediation has been described. In these experiments, one evaluates the relative abundance of A 260 peaks within fixed benzimide gradients before and after remediation treatment to see how the bacterial populations have been affected. The technique relies on the premise that on the average, the GC content of a species is relatively consistent. This technique is applied in the present invention to fractionate complex mixtures of genomes. The nucleic acids derived from a sample are subjected to ultracentrifugation and fractionated while measuring the A 260 as in the published procedures.
  • equal A 260 units are removed from each peak, the nucleic acid is amplified using a variety of amplification protocols known in the art, including those described hereafter, and gene libraries are prepared.
  • equal A 260 units are removed from each peak, and gene libraries are prepared directly from this nucleic acid.
  • gene libraries are prepared from a combination of equal amounts of DNA from each peak. This strategy enables access to genes from minority organisms within environmental samples and enrichments, whose genomes may not be represented or may even be lost, due to the fact that the organisms are present in such minor quantity, if a library was construed from the total unfractionated DNA sample.
  • DNA can be normalized subsequent to fractionation, using techniques described hereafter. DNA libraries can then be generated from this fractionated/normalized DNA. .- 8 -
  • composition of multiple fractions of the fractionated nucleic acid can be determined using PCR related amplification methods of classification well known in the art.
  • NORMALIZATION Previous normalization protocols have been designed for constructing normalized cDNA libraries (WO 95/08647, WO 95/1 1986). These protocols were originally developed for the cloning and isolation of rare cDNA's derived from mRNA. The present invention relates to the generation of normalized genomic DNA gene libraries from uncultured or environmental samples.
  • Nucleic acid samples isolated directly from environmental samples or from primary enrichment cultures will typically contain genomes from a large number of microorganisms. These complex communities of organisms can be described by the absolute number of species present within a population and by the relative abundance of each organisms within the sample. Total normalization of each organisms within a sample is very difficult to achieve. Separation techniques such as optical tweezers can be used to pick morphologically distinct members with a sample. Cells from each member can then be combined in equal numbers or pure cultures of each member within a sample can be prepared and equal numbers of cells from each pure culture combined to achieve normalization. In practice, this is very difficult to perform, especially in a high thru-put manner.
  • the present invention involves the use of techniques to approach normalization of the genomes present within an environmental sample, generating a DNA library from the normalized nucleic acid, and screening the library for an activity of interest.
  • DNA is isolated from the sample and fractionated.
  • the strands of nucleic acid are then melted and allowed to selectively reanneal under fixed conditions (C 0 t driven hybridization).
  • DNA is not - 9 - fractionated prior to this melting process.
  • the common sequences find their complementary strands faster than the rare sequences.
  • single-stranded nucleic acid representing an enrichment of rare sequences, is amplified and used to generate gene libraries. This procedure leads to the amplification of rare or low abundance nucleic acid molecules. These molecules are then used to generate a library. While all DNA will be recovered, the identification of the organism originally containing the DNA may be lost. This method offers the ability to recover DNA from "unclonable sources.”
  • Nucleic acid samples derived using the previously described technique are amplified to complete the normalization process.
  • samples can be amplified using PCR amplification protocols such as those described by Kx> et al. (Ko, 1990b; Ko, 1990a, Takahashi, 1994), or more preferably, long PCR protocols such as those described by Barnes (1994) or Cheng (1994).
  • Normalization can be performed directly, or steps can also be taken to reduce the complexity of the nucleic acid pools prior to the normalization process. Such reduction in complexity can be beneficial in recovering nucleic acid from the poorly represented organisms.
  • the microorganisms from which the libraries may be prepared include prokaryotic microorganisms, such as Eubacteria and Archaebacteria, and lower eukaryotic microorganisms such as fungi, some algae and protozoa.
  • the microorganisms may be cultured microorganisms or uncultured microorganisms obtained from environmental samples and such microorganisms may be extremophiles, such as thermophiles, hyperthermophiles, psychrophiles, psychrotrophs, etc. -. 10 -
  • the library may be produced from environmental samples in which case DNA may be recovered without culturing of an organism or the DNA may be recovered from a cultured organism.
  • Sources of microorganism DNA as a starting material library from which target DNA is obtained are particularly contemplated to include environmental samples, such as microbial samples obtained from Arctic and Antarctic ice, water or permafrost sources, materials of volcanic origin, materials from soil or plant sources in tropical areas, etc.
  • environmental samples such as microbial samples obtained from Arctic and Antarctic ice, water or permafrost sources, materials of volcanic origin, materials from soil or plant sources in tropical areas, etc.
  • genomic DNA may be recovered from either a culturable or non-culturable organism and employed to produce an appropriate recombinant expression library for subsequent determination of enzyme activity.
  • genes Bacteria and many eukaryotes have a coordinated mechanism for regulating genes whose products are involved in related processes.
  • the genes are clustered, in structures referred to as "gene clusters," on a single chromosome and are transcribed together under the control of a single regulatory sequence, including a single promoter which initiates transcription of the entire cluster.
  • the gene cluster, the promoter, and additional sequences that function in regulation altogether are referred to as an "operon" and can include up to 20 or more genes, usually from 2 to 6 genes.
  • a gene cluster is a group of adjacent genes that are either identical or related, usually as to their function.
  • Some gene families consist of identical members. Clustering is a prerequisite for maintaining identity between genes, although clustered genes are not necessarily identical. Gene clusters range from extremes where a duplication is generated to adjacent related genes to cases where hundreds of identical genes lie in a tandem array. Sometimes no significance is discernable in a repetition of a particular gene. A principal example of this is the expressed duplicate insulin genes in some species, whereas a single insulin gene is adequate in other mammalian species.
  • gene clusters undergo continual reorganization and, thus, the ability to create heterogeneous libraries of gene clusters from, for example, bacterial or other prokaryote sources is valuable in determining sources of novel proteins, particularly including enzymes such as, for example, the polyketide synthases that are responsible for the synthesis of polyketides having a vast array of useful activities.
  • enzymes such as, for example, the polyketide synthases that are responsible for the synthesis of polyketides having a vast array of useful activities.
  • Other types of proteins that are the product(s) of gene clusters are also contemplated, including, for example, antibiotics, antivirals, antitumor agents and regulatory proteins, such as insulin.
  • Polyketides are molecules which are an extremely rich source of bioactivities, including antibiotics (such as tetracyclines and erythromycin), anti- cancer agents (daunomycin), immunosuppressants (FK506 and rapamycin), and veterinary products (monensin). Many polyketides (produced by polyketide synthases) are valuable as therapeutic agents. Polyketide synthases are multifunctional enzymes that catalyze the biosynthesis of a huge variety of carbon chains differing in length and patterns of functionality and cyclization. Polyketide synthase genes fall into gene clusters and at least one type (designated type I) of polyketide synthases have large size genes and enzymes, complicating genetic manipulation and in vitro studies of these genes/proteins. - 12 -
  • the ability to select and combine desired components from a library of polyketides and post-polyketide biosynthesis genes for generation of novel polyketides for study is appealing.
  • the method(s) of the present invention make it possible to and facilitate the cloning of novel polyketide synthases, since one can generate gene banks with clones containing large inserts (especially when using the f-factor based vectors), which facilitates cloning of gene clusters.
  • the gene cluster DNA is ligated into a vector, particularly wherein a vector further comprises expression regulatory sequences which can control and regulate the production of a detectable protein or protein-related array activity from the ligated gene clusters.
  • a vector further comprises expression regulatory sequences which can control and regulate the production of a detectable protein or protein-related array activity from the ligated gene clusters.
  • Use of vectors which have an exceptionally large capacity for exogenous DNA introduction are particularly appropriate for use with such gene clusters and are described by way of example herein to include the f-factor (or fertility factor) of E. coli.
  • This f-factor of E. coli is a plasmid which affect high-frequency transfer of itself during conjugation and is ideal to achieve and stably propagate large DNA fragments, such as gene clusters from mixed microbial samples.
  • PVPP polyvinylpolypyrrohdone
  • the tube was then filled with the filtered cesium chloride solution and spun in a VTi50 rotor in a Beckman L8-70 Ultracentrifuge at 33,000 rpm for 72 hours. Following centrifugation, a syringe pump and fractionator (Brandel Model 186) were used to drive the gradient through an ISCO UA-5 UV absorbance detector set to 280 nm. Three peaks representing the DNA from the three organisms were obtained. PCR amplification of DNA encoding rRNA from a 10-fold dilution of the E. coli peak was performed with the following primers to amplify eubacterial sequences:
  • 16S rRNA analysis is used to analyze the complexity of the DNA recovered from environmental samples (Reysenbach, 1992; DeLong, 1992; Barns,
  • Amplification reactions proceed as published.
  • the reaction buffer used in the amplification of the archaeal sequences includes 5% acetamide (Barns, 1994).
  • the products of the amplification reactions are rendered blunt ended by incubation with Pfu DNA polymerase. 5. Blunt end ligation into the pCR-Script plasmid in the presence of
  • Purified DNA is fractionated according to the bis-benzimide protocol of Example (2), and recovered DNA is sheared or enzymatically digested to 3-6 kb fragments. Lone-linker primers are ligated and the DNA is sized selected. Size- selected DNA is amplified by PCR, if necessary.
  • Double-stranded DNA sample is resuspended in hybridization buffer (0.12 M NaH 2 PO 4 , pH 6.8/0.82 M NaCl/1 mM EDTA/0.1% SDS). 2. Sample is overlaid with mineral oil and denatured by boiling for 10 minutes. 3. Sample is incubated at 68°C for 12-36 hours.
  • Double-stranded DNA is separated from single-stranded DNA according to standard protocols (Sambrook, 1989) on hydroxyapatite at 60°C.
  • the single-stranded DNA fraction is desalted and amplified by PCR. 6. The process is repeated for several more rounds (up to 5 or more).
  • Genomic DNA dissolved in TE buffer is vigorously passed through a 25 gauge double-hubbed needle until the sheared fragments are in the desired size range.
  • DNA ends are "polished” or blunted with Mung Bean nuclease. - 17 -
  • DNA is size fractionated using sucrose gradients. 6.
  • Target DNA is ligated to the ⁇ ZAPII vector, packaged using in vitro lambda packing extracts, and grown in the appropriate E. coli XL I Blue host cell.
  • Plates of the library prepared as described in Example 6 are used to multiply inoculate a single plate containing 200 ⁇ L of LB Amp/Meth, glycerol in each well. This step is performed using the High Density Replicating Tool (HDRT) of the Beckman Biomek with a 1% bleach, water, isopropanol, air- dry sterilization cycle between each inoculation.
  • HDRT High Density Replicating Tool
  • the single plate is grown for 2h at 37°C and is then used to inoculate two white 96- well Dynatech microtiter daughter plates containing 250 ⁇ L of LB Amp/Meth, glycerol in each well. The original single plate is incubated at 37°C for 18h, then stored at -80°C.
  • the two condensed daughter plates are incubated at 37°C also for 18 h.
  • the condensed daughter plates are then heated at 70°C for 45 min. to kill the cells and inactivate the host E.coli enzymes.
  • a stock solution of 5mg/mL morphourea phenylalanyl-7- amino-4-trifluoromethyl coumarin (MuPheAFC, the 'substrate') in DMSO is diluted , 18 - to 600 ⁇ M with 50 mM pH 7.5 Hepes buffer containing 0.6 mg/mL of the detergent dodecyl maltoside.
  • the data will indicate whether one of the clones in a particular well is hydrolyzing the substrate.
  • the source library plates are thawed and the individual clones are used to singly inoculate a new plate containing LB Amp/Meth, glycerol. As above, the plate is incubated at 37°C to grow the cells, heated at 70°C to inactivate the host enzymes, and 50 ⁇ L of 600 ⁇ M MuPheAFC is added using the Biomek. Additionally three other substrates are tested.
  • the umbelliferone and rhodamine are added as 600 ⁇ M stock solutions in 50 ⁇ L of Hepes buffer.
  • Chiral amino esters may be determined using at least the following substrates: •
  • the enantiomeric excess is determined by either chiral high performance liquid chromatography (HPLC) or chiral capillary electrophoresis (CE). Assays are performed as follows: two hundred ⁇ L of the appropriate buffer is added to each well of a 96-well white microtiter plate, followed by 50 ⁇ L of partially or completely purified enzyme solution; 50 ⁇ L of substrate is added and the increase in fluorescence monitored versus time until 50% of the substrate is consumed or the reaction stops, whichever comes first.
  • HPLC high performance liquid chromatography
  • CE chiral capillary electrophoresis
  • Example 8 Construction of a Stable, Large Insert Picoplankton Genomic DNA Library Cell collection and preparation of DNA.
  • Agarose plugs containing concentrated picoplankton cells were prepared from samples collected on an oceanographic cruise from Newport, Oregon to Honolulu, Hawaii.
  • Seawater (30 liters) was collected in Niskin bottles, screened through 10 ⁇ m Nitex, and concentrated by hollow fiber filtration (Amicon DC10) through 30,000 MW cutoff polyfulfone filters.
  • the concentrated bacterioplankton cells were collected on a 0.22 ⁇ m, 47 mm Durapore filter, and resuspended in 1 ml of 2X STE buffer (1M NaCl, 0.1M EDTA, 10 mM Tris, pH 8.0) to a final density of approximately 1 x 10 10 cells per ml.
  • the cell suspension was mixed with one volume of 1% molten Seaplaque LMP agarose (FMC) cooled to 40°C, and then immediately drawn into a 1 ml syringe. The syringe was sealed with parafilm and placed on ice for 10 min.
  • FMC Seaplaque LMP agarose
  • the cell-containing agarose plug was extruded into 10 ml of Lysis Buffer (lOmM Tris pH 8.0, 50 mM NaCl, 0.1M EDTA, 1% Sarkosyl, 0.2% sodium deoxycholate, 1 mg/ml lysozyme) and incubated at 37°C for one hour.
  • Lysis Buffer lOmM Tris pH 8.0, 50 mM NaCl, 0.1M EDTA, 1% Sarkosyl, 0.2% sodium deoxycholate, 1 mg/ml lysozyme
  • the agarose plug was then transferred to 40 mis of ESP Buffer (1% Sarkosyl, 1 mg/ml proteinase K, in 0.5M EDTA), and incubated at 55°C for 16 hours.
  • the solution was decanted and - 21 - replaced with fresh ESP Buffer, and incubated at 55°C for an additional hour.
  • the agarose plugs were then placed in 50 m
  • the solution was then changed to 250 ⁇ l of the same buffer containing 4U of Sau3Al (NEB), equilibrated to 37°C in a water bath, and then incubated on a rocking platform in a 37°C incubator for 45 min.
  • the plug was transferred to a 1.5 ml microcentrifuge tube and incubated at 68°C for 30 min to inactivate the enzyme and to melt the agarose.
  • the agarose was digested and the DNA dephosphorylased using Gelase and HK-phosphatase (Epicentre), respectively, according to the manufacturer's recommendations. Protein was removed by gentle phenol/chloroform extraction and the DNA was ethanol precipitated, pelleted, and then washed with 70% ethanol. This partially digested DNA was resuspended in sterile H 2 O to a concentration of 2.5 ng/ ⁇ l for ligation to the pFOSl vector.
  • Agarose plugs prepared from this picoplankton sample were chosen for subsequent fosmid library preparation.
  • Each 1 ml agarose plug from this site contained approximately 7.5 x 10 5 cells, therefore approximately 5.4 x ⁇ cells were present in the 72 ⁇ l slice used in the preparation of the partially digested DNA.
  • Vector arms were prepared from pFOS 1 as described (Kim et al. , Stable propagation of casmid sized human DNA inserts in an F factor based vector. Nucl. Acids Res., 20:10832-10835, 1992). Briefly, the plasmid was completely digested with Astll, dephosphorylated with HK phosphatase. and then digested with BamHI to generate two arms, each of which contained a cos site in the proper orientation for cloning and packaging ligated DNA between 35-45 kbp.
  • the partially digested picoplankton DNA was ligated overnight to the PFOS1 arms in a 15 ⁇ l ligation reaction containing 25 ng each of vector and insert and 1U of T4 DNA ligase (Boehringer-Mannheim).
  • the ligated DNA in four microliters of this reaction was in vitro packaged using the Gigapack XL packaging system (Stratagene), the fosmid particles transfected to E. coli strain DH10B (BRL), and the cells spread onto LB cml5 plates.
  • the resultant fosmid clones were picked into 96-well microliter dishes containing LB cml5 supplemented with 7% glycerol. Recombinant fosmids, each containing ca.
  • AFC 7-amino- -tr.fiuorome(hyl cnumvin.)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un procédé permettant la constitution d'une échantillothèque normalisée d'ADN génomique à partir d'un échantillon prélevé dans son milieu. Ce procédé consiste d'abord (a) à isoler dans l'échantillon prélevé dans son milieu une population d'ADN génomique. Le procédé consiste ensuite à réaliser l'une au moins des deux opérations consistant (i) à amplifier le nombre d'exemplaires de la population d'ADN ainsi isolée ou (ii) à récupérer une fraction de l'ADN génomique isolé présentant une caractéristique intéressante. Le procédé consiste enfin (c) à normaliser la représentation des divers ADN dans la population d'ADN génomique de façon à constituer une échantillothèque normalisée d'ADN génomique à partir de l'échantillon prélevé dans son milieu. L'invention concerne également une échantillothèque normalisée d'ADN génomique obtenue selon ce procédé à partir d'un échantillon prélevé dans son milieu.
EP99909874A 1998-03-04 1999-03-04 Production et utilisation d'echantillotheques d'adn normalisees Withdrawn EP1060269A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34724 1998-03-04
US09/034,724 US6001574A (en) 1996-06-18 1998-03-04 Production and use of normalized DNA libraries
PCT/US1999/004917 WO1999045154A1 (fr) 1998-03-04 1999-03-04 Production et utilisation d'echantillotheques d'adn normalisees

Publications (2)

Publication Number Publication Date
EP1060269A1 true EP1060269A1 (fr) 2000-12-20
EP1060269A4 EP1060269A4 (fr) 2004-10-27

Family

ID=21878199

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99909874A Withdrawn EP1060269A4 (fr) 1998-03-04 1999-03-04 Production et utilisation d'echantillotheques d'adn normalisees

Country Status (6)

Country Link
EP (1) EP1060269A4 (fr)
JP (1) JP2002505121A (fr)
AU (1) AU744699B2 (fr)
CA (1) CA2321930A1 (fr)
MX (1) MXPA00008559A (fr)
WO (1) WO1999045154A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8476011B1 (en) * 1996-06-18 2013-07-02 Bp Corporation North America Inc. Construction and use of catalogued nucleic acid libraries that contain advantageously adjusted representations of defined components
US5763239A (en) 1996-06-18 1998-06-09 Diversa Corporation Production and use of normalized DNA libraries
US6326204B1 (en) 1997-01-17 2001-12-04 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
US6399334B1 (en) * 1997-09-24 2002-06-04 Invitrogen Corporation Normalized nucleic acid libraries and methods of production thereof
JP2002522072A (ja) 1998-08-12 2002-07-23 マキシジェン， インコーポレイテッド 工業用化学薬品の製造のためのモノオキシゲナーゼ遺伝子のｄｎａシャッフリング。
AU6510799A (en) 1998-10-07 2000-04-26 Maxygen, Inc. Dna shuffling to produce nucleic acids for mycotoxin detoxification
AU1619400A (en) 1998-11-10 2000-05-29 Maxygen, Inc. Modified adp-glucose pyrophosphorylase for improvement and optimization of plantphenotypes
US6376246B1 (en) 1999-02-05 2002-04-23 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US6436675B1 (en) 1999-09-28 2002-08-20 Maxygen, Inc. Use of codon-varied oligonucleotide synthesis for synthetic shuffling
CA2361384A1 (fr) 1999-02-11 2000-08-17 Sun Ai Raillard Spectrometrie de masse a haut rendement
US6531316B1 (en) 1999-03-05 2003-03-11 Maxyag, Inc. Encryption of traits using split gene sequences and engineered genetic elements
US6686515B1 (en) 1999-11-23 2004-02-03 Maxygen, Inc. Homologous recombination in plants
FR2808276B1 (fr) 2000-04-26 2004-04-02 Renaud Nalin Procede d'extraction indirecte de l'adn d'organismes non cultivables et adn susceptible d'etre obtenu par ledit procede
WO2002000717A2 (fr) 2000-06-23 2002-01-03 Maxygen, Inc. Nouvelles molecules costimulatrices
US6858422B2 (en) 2000-07-13 2005-02-22 Codexis, Inc. Lipase genes
US7838287B2 (en) 2001-01-25 2010-11-23 Evolva Sa Library of a collection of cells
US8008459B2 (en) 2001-01-25 2011-08-30 Evolva Sa Concatemers of differentially expressed multiple genes
EP1386966A1 (fr) 2002-07-24 2004-02-04 Libragen Méthode pour l'expresssion de l'ADN environmental dans des cellules hôtes

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995008647A1 (fr) * 1993-09-24 1995-03-30 The Trustees Of Columbia University In The City Of New York PROCEDE D'ELABORATION DE BANQUES D'ADNc NORMALISEES
WO1997048717A1 (fr) * 1996-06-18 1997-12-24 Recombinant Biocatalysis, Inc. Production et utilisation de banques normalisees d'adn

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995008647A1 (fr) * 1993-09-24 1995-03-30 The Trustees Of Columbia University In The City Of New York PROCEDE D'ELABORATION DE BANQUES D'ADNc NORMALISEES
WO1997048717A1 (fr) * 1996-06-18 1997-12-24 Recombinant Biocatalysis, Inc. Production et utilisation de banques normalisees d'adn

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9945154A1 *

Also Published As

Publication number Publication date
CA2321930A1 (fr) 1999-09-10
WO1999045154A1 (fr) 1999-09-10
AU744699B2 (en) 2002-02-28
AU2898199A (en) 1999-09-20
JP2002505121A (ja) 2002-02-19
EP1060269A4 (fr) 2004-10-27
MXPA00008559A (es) 2005-06-06

Similar Documents

Publication Publication Date Title
US5763239A (en) Production and use of normalized DNA libraries
McGlincy et al. Transcriptome-wide measurement of translation by ribosome profiling
AU744699B2 (en) Production and use of normalized DNA libraries
JP6557151B2 (ja) 混合物中の核酸を配列決定する方法およびそれに関する組成物
CN113166797A (zh) 基于核酸酶的rna耗尽
US20080045418A1 (en) Method of labeling and profiling rnas
AU2007225499A1 (en) Nucleic acid interaction analysis
US20080096255A1 (en) Method for Preparing Sequence Tags
US10900974B2 (en) Methods for identifying macromolecule interactions
EP3988669A1 (fr) Procédé de detection d'acides nucléiques par oligo hybridation et amplification à base de pcr
AU765207B2 (en) Construction and use of catalogued nucleic acid libraries that contain advantageously adjusted representations of defined components
AU777951B2 (en) Production and use of normalized DNA libraries
US20240141325A1 (en) Generation of novel crispr genome editing agents using combinatorial chemistry
KR20230163386A (ko) 증폭된 라이브러리에서 바람직하지 않은 단편을 선택적으로 고갈시키기 위한 차단 올리고뉴클레오티드

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20001004

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20040913

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DIVERSA CORPORATION

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20060808

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1033474

Country of ref document: HK